adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector

RxCUI: 2640287
RxNorm name: adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector
Display name: adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector
Full name: adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761059	Hadlima	adalimumab-bwwd	351(k) Interchangeable	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
HADLIMA	ADALIMUMAB-BWWD	A-S Medication Solutions	ef25af7e-6267-409a-8d68-de51eb48812a	2023-10-02	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2640287

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
4774a951-3ce8-43b6-80b1-e6b23752aae6	adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector [PSN] · 0.8 ML adalimumab-bwwd 50 MG/ML Auto-Injector [SCD] · adalimumab-bwwd 40 MG per 0.8 ML Auto-Injector [SY]	3	13	These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee	20251017
ef25af7e-6267-409a-8d68-de51eb48812a	adalimumab-bwwd 40 MG in 0.8 ML Auto-Injector [PSN] · 0.8 ML adalimumab-bwwd 50 MG/ML Auto-Injector [SCD] · adalimumab-bwwd 40 MG per 0.8 ML Auto-Injector [SY]	3	1	These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar* to HUMIRA (adalimumab)	20231002